Valuation dashboard for MediciNova, Inc. (MNOV) with P/E N/A, P/B 3.65, EV/EBITDA -5.72 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
Analysis Summary
Trailing-twelve-month margins: gross margin 42.4%, operating margin -12.9%, net margin -11.7%.
At the current price of $2.52, MNOV has negative trailing earnings (P/E not meaningful) and an ROE of -26.51%. Market capitalisation stands at $124M.
Balance sheet quality for MNOV: current ratio of 8.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.65 |
| EV / EBITDA | -5.72 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MNOV | MediciNova, Inc. | $124M | 3.65 | -26.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.52 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -26.51% |
| Return on Invested Capital | -31.53% |
| Return on Assets | -26.59% |
| Gross Margin | 42.39% |
| Operating Margin | -1287.41% |
| Net Margin | -1168.20% |
Related companies: ACRV · BMEA · CBUS · FBIO · IMUX · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of MNOV: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks